Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
CNS Drugs
Published in: CNS Drugs 11/2005

01-11-2005 | Adis Drug Profile

Rotigotine

A Viewpoint by Peter LeWitt

Author: Peter LeWitt

Published in: CNS Drugs | Issue 11/2005

Login to get access

Excerpt

While the amino acid precursor of dopamine provides the most effective reversal of Parkinson’s disease (PD) symptomatology, other pharmacological options have joined levodopa in the dopaminergic armamentarium for this disorder. Drugs termed ‘dopaminergic agonists’ have been a major focus of drug development ever since the first of these, bromocriptine, was introduced in 1974. …
Literature
1.
LeWitt PA. Pharmacology of dopaminergic agonists for Parkinson’s disease. In: LeWitt PA, Oertel WH, editors. Parkinson’s disease: the treatment options. London: Martin Dunitz Publishers, 1999: 159–86
2.
Newman-Tancredi A, Cussac D, Audinot V, et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor. J Pharmacol Exp Ther 2002 Nov; 303(2): 805–14PubMedCrossRef
3.
Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000 May 18; 342(20): 1484–91CrossRef
4.
Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004 Jul; 61(7): 1044–53PubMedCrossRef
5.
The Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000 Oct 18; 284(15): 1931–8CrossRef
6.
Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson’s disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 2003 Jul; 54(1): 93–101PubMedCrossRef
7.
The Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002 Apr 3; 287(13): 1653–61CrossRef
8.
Hutton JT, Metman LV, Chase TN, et al. Transdermal dopaminergic D2 receptor agonist therapy in Parkinson’s disease with N-0923 TDS: a double-blind, placebo-controlled study. Mov Disord 2001 May; 16: 459–63PubMedCrossRef
9.
Metman LV, Gillespie M, Farmer C, et al. Continuous transdermal dopaminergic stimulation in advanced Parkinson’s disease. Clin Neuropharmacol 2001; 24(3): 163-9PubMedCrossRef
Metadata
Title
Rotigotine
A Viewpoint by Peter LeWitt
Author
Peter LeWitt
Publication date
01-11-2005
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 11/2005
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.2165/00023210-200519110-00008

Other articles of this Issue 11/2005

CNS Drugs 11/2005 Go to the issue

Review Article

The Use of Triptans in the Management of Menstrual Migraine

Adis Drug Profile

Rotigotine

Review Article

Advances in Drug Treatments for Children and Adolescents with Autism and Other Pervasive Developmental Disorders

Adis Drug Profile

Rotigotine

Review Article

Head-To-Head Comparison of the Costs of Atypical Antipsychotics

Current Opinion

Overtreatment in Epilepsy